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Abstract: (1) Background: One mechanism through which physical activity (PA) provides benefits is
by triggering activity at a molecular level, where neurotrophins (NTs) are known to play an impor-
tant role. However, the expression of the circulating levels of neurotrophic factors, brain-derived
neurotrophic factor (BDNF) and neurotrophin-4 (NT-4/5), in response to exercise, is not fully under-
stood. Therefore, the aim was to provide an updated overview on the neurotrophin (NT) variation
levels of BDNF and NT-4/5 as a consequence of a long-term aerobic exercise intervention, and to
understand and describe whether the upregulation of circulating NT levels is a result of neurotrophic
factors produced and released from the brain, and/or from neurotrophic secreting peripheral organs.
(2) Methods: The articles were collected from PubMed, SPORTDiscus, Web of Science, MEDLINE,
and Embase. Data were analyzed through a narrative synthesis. (3) Results: 30 articles studied
humans who performed training protocols that ranged from 4 to 48 weeks; 22 articles studied rodents
with an intervention period that ranged from 4 to 64 weeks. (4) Conclusions: There is no unanimity
between the upregulation of BDNF in humans; conversely, concerning both BDNF and NT-4/5 in
animal models, the results are heterogeneous. Whilst BDNF upregulation appears to be in relative
agreement, NT-4/5 seems to display contradictory and inconsistent conclusions.
Keywords: exercise; neurotrophins; brain-derived neurotrophic factor; neurotrophin-4; peripheral
circulation
1. Introduction
There is growing evidence that insufficient physical activity (PA), highly linked with
society’s modern-day sedentary lifestyle, is a major contributor to the increased risk of
various health-related problems [1]. On the other hand, it has been well established
that PA provides various stimuli that are capable of enhancing both the metabolic and
functional status of the human body [2]. Regular PA has evidenced an improvement of the
physiological performance of the skeletal and cardiac muscles and, in addition, the decrease
of the incidence of a wide range of diseases, including multiple types of cancers, type 2
diabetes, osteoporosis, and brain disease [3]. PA has particularly been known to provoke a
cascade of molecular and cellular processes that naturally support brain plasticity [4]. One
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central mechanism which accounts for the modifications that occur in brain morphology
and plasticity is through PA and its ability to produce, release, and regulate growth factors
that influence the development of structural and functional changes on the brain [5].
Growth factors are proteins that control various aspects of cellular function, involving
survival, proliferation, migration, and differentiation [6]. Subsequently, when considered in
the context of the nervous system, the formerly cited growth factors are regularly referred to
as neurotrophic factors [7]. To date, four members have been identified as belonging to the
mammalian neurotrophic family; nerve growth factor (NGF), brain-derived neurotrophic
factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4, also referred to as neurotrophin-
4/5 (NT-4/5) [8]. Each of these neurotrophic factors bind to one or more cellular receptors
and mediate their physiological functions [9].
BDNF, one of the most widely reviewed neurotrophic factors belonging to the mam-
malian family, and NT-4/5, bind to the tyrosine kinase B receptor (trkB) [10]. Moreover,
since both bind to the same receptor, it is thought that their roles may be, to a certain extent,
similar [11]. BDNF and NT-4/5 also share more than 50% of amino acid homology [12].
Originally, neurotrophins (NTs) were characterized and limited to their role in initial
development, growth, maintenance, and the plasticity of the nervous system throughout
development, however, current up-to-date literature has indicated the complex role they
fulfill during normal physiology in numerous cell populations across both central and
peripheral nervous systems, as well as in neuronal and non-neuronal tissues [10,13–15].
Although literature in this respect has been fairly inconsistent, recent reports on human
and animal models have attempted to examine the impact and link between PA and
the upregulation of neurotrophic factor expression and concentrations in multiple body
compartments such as the brain, blood, and muscle. Among the numerous well-known
exercise training interventions developed throughout these past years, there seems to be
a body of evidence reporting that aerobic exercise appears to increase the expression of
NTs, particularly BDNF [9,16–18]. Contrarily, less clear, and a rather limited number of
studies have evaluated the influence of PA on other NTs, such as NT-4/5 [9]. To date,
the evidence seems to suggest that there is no sort of unanimity within the relationship
between PA, more specifically aerobic exercise, and a consequential NT-4/5 upregulation
within compartments.
One of the main reasons related to the inconsistencies between neurotrophic factor
upregulation results and PA is mainly due to discrepancies linked with the heterogeneity
between participants characteristics (age, health, status, diseases, etc.), study duration,
different intervention exercise programs [4,19], as well as specific methodological consider-
ations, such as blood processing conditions (plasma, serum or whole blood) and timing of
collection [4,20], among others. As aforementioned, taken into account that both BDNF
and NT-4/5 initiate their intracellular signaling via identical cell surface receptors, it is of
interest the reason NT-4/5 has not been evaluated following similar exercise conditions
when compared with its neurotrophic counterpart, BDNF [21]. Secondly, according to Pan
and colleagues (1998) [22], most members of the mammalian NT family, including BDNF
and NT-4/5, appear to cross the blood-brain barrier (BBB), through saturable transport
systems, to arrive intact in the central nervous system (CNS), suggesting the possible
existence of an exercise-induced neurotrophic crosstalk [23]. Consequently, this increases
the difficulty to identify whether in human and animal models these neurotrophic factor
fluctuations in serum levels result from changes in central or peripheral tissues. Therefore,
the current review aims to provide an updated overview of the NT variation levels of
both BDNF and NT-4/5 as a consequence of a long-term aerobic exercise intervention.
We will also discuss whether the upregulation of circulating NT levels is a result of the
neurotrophic factors produced and released from the brain (cerebral circulation) or, under
other conditions, from peripheral organs (peripheral circulation).
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2. Methods
The manuscript was authored in agreement with the principles of the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [24],
having partially adopted the checklist. The protocol was not pre-registered, but was written
and approved by the authors before the collection process. Multiple electronic databases
were systematically searched from the commencement until 7 July 2020, correspondingly
identifying articles published before this date (no restriction was placed on how far back the
articles were published). The electronic databases PubMed, SPORTDiscus, Web of Science,
MEDLINE, and Embase were used. The following search-term categories were used
independently as well as in combination: neurotrophins (e.g., BDNF and neurotrophin-
4/5), exercise (e.g., aerobic exercise, treadmill, cycling, swimming), and circulation (e.g.,
cerebral and peripheral circulation).
The Population, Intervention, Comparator, Outcomes, and Study design (PICOS)
framework design was adopted to create the eligibility criteria for the inclusion of articles
in this review. This review included adults (>18 years) and animal models with no restric-
tions regarding physical or cognitive conditions. Therefore, studies involving individuals
with risk factors (e.g., overweight, obesity, diabetes), with known cardiometabolic diseases
(e.g., Type 2 diabetes, coronary heart disease), or neurological disorders (e.g., Alzheimer’s
disease, depression, mild cognitive impairment) were, too, eligible for inclusion. This
review included experimental studies that focused on aerobic exercise intervention models.
Any other form of exercise (strength training, HIIT, etc.) was not contemplated in this
review. Concerning animal protocols, albeit voluntary wheel-running exercise has been as-
sociated in diminishing the potential confounding factor of stress, only forced, involuntary
exercise protocols were included as they allow control of the intensity, duration, and timing
of the exercise. Restrictions regarding the duration of the intervention were considered.
A 4-week training protocol was defined as being the minimum duration-period to be
contemplated in this review. Control groups and baseline measurements were considered
comparators for intervention effect values. Only original, peer-reviewed, English-language
literature was examined. Reviews, meta-analyses, books, book reviews, abstracts, scientific
conference abstracts, opinion articles, statements, editorials, letters, and commentaries
were excluded.
Data Collection, Extraction, and Analysis
To identify potentially eligible articles, two investigators independently screened the
titles and abstracts acquired from the retrieved articles through the electronic search accord-
ing to the inclusion and exclusion criteria. Subsequently, after this first selection, full-length
articles were read by the same investigators to define which articles consequently met
all the inclusion criteria. Nonetheless, in the case of hypothetical inconsistencies or dis-
agreements concerning inclusion or data extraction, a third independent investigator was
consulted. Investigators were not blinded to the titles, authors, institutions or manuscript
content during the selection process.
Within each of the identified studies, multiple variables were evaluated to determine
if they deliberated the association between an aerobic exercise intervention and the changes
in BDNF and NT-4/5 levels from pre-exercise to post-exercise. A standardized electronic
data extraction method form was developed to obtain information pertinent to this review.
Data withdrawal for each article, extracted into the preformatted spreadsheet by two raters,
include information regarding: population studied (exercise group vs. control group),
sample size, BDNF & NT-4/5 measurement technique used (analysis technique), time of
measure, duration, type, and intensity of exercise, as well as the main outcomes. The last
item—main outcomes—involves the variation levels of BDNF and NT-4/5 concentrations
(increased, decreased, or no change) between pre- and post-exercise intervention values. A
subset analysis has also been conducted examining the effects of interventions of less than
12 weeks, between 12 and 36 weeks, and more than 36 weeks. Furthermore, an analysis
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based on the exercise type and population of the study has also been performed. Data were
analyzed through a narrative synthesis.
3. Results
An initial raw screening resulted in a selection of 907 articles. Following the titles,
abstracts, and a full-text article selection, based on specific predetermined criteria, our
search resulted in a final selection of 49 reports (Figure 1).
Figure 1. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow chart.
Regarding the relationship between chronic aerobic exercise interventions and the
variation of BDNF blood concentration levels on human subjects, 30 human studies (Table 1)
were detected, with a heterogeneous study population varying from young individuals to
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elderly groups; as well as from healthy study populations to groups with a wide spectrum
of medical conditions (e.g., multiple sclerosis [MS], Parkinson’s and Alzheimer’s disease,
major depressive disorder [MDD], obese and overweight individuals, etc.). The duration
of the exercise protocols varied from 4- to 48-week exercise intervention programs. A wide
repertoire of exercise modalities were observed between reports, varying from swimming,
treadmill running, cycling, rowing, etc., with the intensity of exercise being relatively
similar between the below-mentioned screened articles (moderate-to-vigorous aerobic
intensity varying from ±50–80% of VO2max). Most of the analyzed reports (n = 24)
assessed BDNF measurements from serum samples, whilst some (n = 8) used plasma as an
alternative measure, and one study, alone, adopted platelet BDNF as an assessment sample.
Between all 30 studies conducted on human subjects, the conclusions and main-outcomes
varied considerably; within the 30 analyzed, 33 group comparators were established. Of
these, 12 in total, which represent ≈36.4% of the entire scope of the review, determined no
change whatsoever on the BDNF serum concentration levels post-exercise intervention,
when compared with the pre-exercise BDNF concentration values and with the controls; a
total of 17 comparators, which represent ≈51.5% of the whole scope of studies, concluded
an increase in BDNF concentration levels from pre- to post-exercise intervention; lastly,
four comparators determined a decrease in BDNF levels, representing ≈12.1% of the total
scope of reviewed articles in Table 1.
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Table 1. Summary of studies that have reviewed the relationship between a chronic aerobic exercise intervention and the variation of BDNF blood concentration levels in human subjects.
Author(s)
Population Studied
(Exercise Group n vs.
Control Group n)
n BDNF Measure(Analysis Technique) Time of Measure Duration of Exercise
Aerobic Exercise











Group-C-Ex3 n = 9 vs.
5-week Aerobic Exercise
Group C-Ex5 n = 9 vs.
Sedentary Non-Exercise





3 weeks & 5 weeks stationary cycle ergometer(3 days/week) 60% VO2max
3 weeks of cycling training
presented no effect on serum
BDNF concentration; however,
an increase of serum BDNF
concentration was observed at
week 5.
Salehi, et al. (2016) [26]
Major Depressive Disorder
Patients (Aerobic Exercise
Group n = 20)
20 Plasma (ELISA) pre- and postintervention 4 weeks
cycling on a
treadmill (3 days/week) 60–75% of VO2max
Pre- to post-assessment
plasma BDNF levels were
increased in the Aerobic
Exercise Training group.
Zoladz, et al. (2008) [27]
Healthy Physically Active
Young Men (Exercise Group
n = 13)
13 Plasma (ELISA) pre- and postintervention 5 weeks
cycle ergometer
(4 days/week)
90% of VO2 at
lactacte threshold
A 5-week exercise program of
moderate intensity endurance
training resulted in a
significant “chronic” increase
in the basal, as well as in the
exercise induced “acute”
increase in plasma BDNF
levels.
Kerling, et al. (2017)
[28]
Depressed Inpatients
(Aerobic Exercise Group +
Treatment as Usual n = 22
vs. Treament as Usual











An increase in serum BDNF in
the exercise group was
detected. Alterations over
time reached no statistical
significance in both groups.
The Treatment as Usual
Control Group serum BDNF
levels decreased slightly.
Exercise appears to have
additional effects on BDNF
serum concentrations in
people with major depressive
disorder.
Babaei, et al. (2013) [29]
Metabolic Syndrome (MetS)
and Healthy Middle-Aged
Males (MetS-Exercise n = 11
vs. MetS-Control n = 10 vs.
Healthy-Exercise n = 11 vs.
Healthy-Control n = 10)






After aerobic exercise, BDNF
levels significantly increased
in the Healthy Exercise Group,
but decreased in the Metabolic
Syndrome Exercise Group.




(Exercise Group n vs.
Control Group n)
n BDNF Measure(Analysis Technique) Time of Measure Duration of Exercise
Aerobic Exercise











Exercise Group n = 11 vs.
Non-exercise Control Group
n = 10)




50–60% of VO2 peak
Serum BDNF significantly
decreased after chronic aerobic
training in the Metabolic
Syndrome exercise group
subjects (Blood samples were
collected at the end of the
6-week training).
Wagner, et al. (2017)
[31]
Male Students (Aerobic
Exercise Group n = 17 vs.
Control Group n = 17)
34 Serum (ELISA) pre- and postintervention 6 weeks
bicycle ergometer
(3 days/week)
77± 9% of pre-training
VO2max (ranging from
60% to 88%)
The results indicate a decrease
in the exercise-induced BDNF
concentration after the
intervention in the exercise









Multiple Sclerosis (MS) (MS
Exercise Group n = 11 vs.
Healthy Exercise Control








(3 days/week) 60% VO2peak
Resting serum BDNF was
significantly lower in MS
compared to control subjects
at week 0, but was not
significantly different at week
8. In the MS exercise group, an
elevated concentration of
serum BDNF was observed
following 4 weeks of training
with a return to baseline at
week 8. Non-significant
difference in the MS group at 8
weeks. In contrast, resting
BDNF concentrations
remained unchanged at 4 and
8 weeks of training in controls.
Cho & Roh (2016) [33]
Young Obese Men (Aerobic
Exercise Group n = 8 vs.
Non-Exercise Control
Group n = 8)
16 Serum (ELISA) pre- and postintervention 8 weeks
treadmill running
(3 days/week)




training), serum BDNF levels
were significantly higher than
those prior to the intervention
in the exercise group of obese
individuals.




(Exercise Group n vs.
Control Group n)
n BDNF Measure(Analysis Technique) Time of Measure Duration of Exercise
Aerobic Exercise






El-Tamawy, et al. (2014)
[34]
Ischemic Stroke Patients (G2
subjected to a physiotherapy
program followed by





30 Serum (ELISA) pre- and postintervention 8 weeks
bicycle ergometer
(3 days/week) n.d.
Aerobic exercise, following an
acute ischemic stroke, is
accompanied by an increase in
the serum levels of BDNF. At
the end of the treatment,
compared with the
pre-concentration levels, there
was a significant increase in
the serum BDNF levels within
the exercise group, while the
control group showed no
significant increase in the
serum BDNF levels.
Goekint, et al. (2010)
[35]
Young Sedentary Students
(Exercise Group n = 9 vs.
Physically Inactive Control
Group n = 7)






concentration levels were not
influenced by an 8 week
aerobic training protocol.





Exercise Group n = 11 vs.
Healthy Non-Trained











The BDNF serum levels
increased in the Parkinson
Disease Patients from the
exercise group, whereas no
change was observed in the
Healthy Control Group.
Training resulted in an
increase in BDNF levels
relative to the pre-training
values.
Roh & So (2016) [37]
Obese and Non-Obese Men
(Obese Exercise Group
n = 10 vs. Healthy
Non-Obese Exercise Group
n = 10)
20 Serum (ELISA) pre- and postintervention 8 weeks
treadmill running
(3 days/week) 70% heart rate reserve
The obese group showed a
significantly lower BDNF level
at baseline compared with the
non-obese group. The
non-obese group showed no
significant difference in blood
neurotrophic factor levels
before and after training,
whereas the obese group
showed a significantly higher
BDNF level after training.
Schulz, et al. (2004) [38]
Multiple Sclerosis (MS)
(Exercise Group n = 15 vs.
Control-no
intervention-Group n = 13)
28 Serum (ELISA) pre- and postintervention 8 weeks
bicycle ergometer
(2 days/week) 60% VO2max
Although not with statistical
significance, an increase of
BDNF levels was seen in the
MS training group, while the
levels in the MS control group
decreased.




(Exercise Group n vs.
Control Group n)
n BDNF Measure(Analysis Technique) Time of Measure Duration of Exercise
Aerobic Exercise






Zoladz, et al. (2014) [39]
Patients with Idiopatic
Parkinson’s Disease
(Exercise Group n = 12)
12 Serum (ELISA) pre- and postintervention 8 weeks
stationary cycle ergometer
(3 days/week) 60–75% of HRmax
Serum BDNF levels increased
significantly after an 8-week
moderate-intensity interval
training intervention in the
Parkinson Disease Exercise
Patients.
Enette, et al. (2020) [40]




Group-CAT n = 14 vs. vs.
Control Group n = 21)
35 Plasma (ELISA) pre- and postintervention at week 10 9 weeks
cycle ergometer
(2 days/week) 70% of HRmax
9 weeks of continuous aerobic
training failed to induce
significant plasma BDNF
response compared to baseline
levels. No significant change
was measured in terms of
plasma BDNF levels after the
training program.
Briken, et al. (2016) [41]





bicycle ergometry n = 28 vs.
Control Group n = 9)
37 Serum (ELISA) pre- and postintervention 9 weeks




BDNF serum levels did not
increase significantly after a
training intervention of
22 sessions in comparison to
the control group. Long-term
effects of BDNF are less
pronounced when compared
with acute exercise.










overweight and obese subjects,
serum and platelet BDNF
circulating levels increased
after 30 sessions of aerobic
exercise.
12–36 weeks
Kimhy, et al. (2015) [43]
Schizophrenia or Related
Disorder Individuals
(Aerobic Exercise Group +
Treatment As Usual n = 16
vs. Control Treatment As
Usual Group n = 17)
33 Serum (ELISA) pre- and postintervention 12 weeks




At follow-up, BDNF increased
in the Aerobic Exercise group.
Group difference changes in
BDNF did not reach
significance, potentially due to
the small sample size.
Krogh, et al. (2014) [44]
Major Depression Patients
(Aerobic Exercise Group
n = 41 vs. Control Group
n = 38)
79 Serum (ELISA) pre- and postintervention 12 weeks
stationary bikes
(3 days/week) 80% of HRmax
A 3-month aerobic exercise
training program did not
increase BDNF serum levels.
No differences were found in
serum BDNF between the
aerobic exercise group and the
control group in the
post-intervention samples.




(Exercise Group n vs.
Control Group n)
n BDNF Measure(Analysis Technique) Time of Measure Duration of Exercise
Aerobic Exercise






Maass, et al. (2016) [45]
Healthy Sedentary Older
Adults (Aerobic Exercise
Group n = 21 vs. Control
Group n = 19)





65% of target heart rate
+5% in steps for
4 weeks
BDNF did not significantly
change between pre- and post
exercise levels. The 3-month
intervention did not alter
BDNF levels in the blood.




Group n = 29 vs.
Non-Exercise Control
Group n = 24)
53 Serum (ELISA) pre- and postintervention 12 weeks
cycle ergometer
(3 days/week) 64 ± 9% VO2 max
No effect of aerobic exercise
training was seen on serum
BDNF concentrations
compared with the control
group.
Seifart, et al. (2010) [47]
Healthy Sedentary Males
(Endurance Training n = 7
vs. Sedentary Controls
n = 5)
12 Plasma (ELISA) pre- and postintervention 12 weeks
cycling, running, swimming
or rowing (7 days/week)




3 months of endurance
training enhanced the resting
release of BDNF, with no
significant change in the
control group. There was no
training-induced increase in
the release of BDNF during
exercise.




Training Group vs. Control
Group)
27 Plasma (ELISA) pre- and postintervention 12 weeks treadmill (3 days/week)
80% of the HR at the
aerobic-anaerobic
threshold
There were no significant
changes for BDNF. The
authors suggest that exercise





Physically Active & Healthy
Young Subjects (n = 18) 18 Serum (ELISA)
pre- and post
intervention 12 weeks jogging (3 days/week)
between 65–70% of
HRmax
BDNF was unchanged in
response to the moderate
intensity training program. A
12 week aerobic training
program of moderate intensity,
completed by healthy subjects,
did not result in an increase in
BDNF concentrations.
Baker, et al. (2010) [50]
Adults with Amnestic Mild
Cognitive Impairment
(High-Intensity Aerobic
Exercise Group n = 19 vs.
Stretching Control Group
n = 10)





75% to 85% of HR
reserve
Relative to controls, aerobic
exercise increased circulating
levels of BDNF in men
patients and decreased levels
of BDNF in women.




(Exercise Group n vs.
Control Group n)
n BDNF Measure(Analysis Technique) Time of Measure Duration of Exercise
Aerobic Exercise






Cho, et al. (2014) [51]
Healthy Middle-Aged
Women (Aerobic-Exercise
Group n = 15 vs. vs.
Non-exercise Control Group
n = 7)
22 Serum (ELISA) pre- and postintervention 24 weeks treadmill (4 days/week)
between 50–80% of
VO2max
After 24 weeks, there were
significant serum BDNF level
changes in the aerobic exercise







Group n = 20 vs. Exercise
Gymnastics Low-Intensity
Aerobic Group n = 21 vs.
No Intervention Control
Group n = 21)










Change in physical activity
levels with the intervention
showed a trend for a positive
association with the change in
BDNF levels. The authors
detected a trend of an increase
in BDNF with increasing
physical activity over six
months.
>36 weeks
Swift, et al. (2012) [53]
Type 2 Diabetes Individuals
(Aerobic Training Only
n = 40 vs. Resistance
Training Only n = 44 vs.
Combination of Resistance








intervention 36 weeks treadmill (150 min/week)
between 50–80% of
VO2max
Serum BDNF measures were






















50–60% of HR reserve
(1–7 weeks) 60–75% HR
reserve (remainder of
the program)
The aerobic exercise group did
not demonstrate greater
changes in circulating serum
BDNF levels compared with
the control group. However,
the aerobic exercise group
revealed higher
post-intervention BDNF levels,
when compared with the
pre-intervention BDNF
concentrations.
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3.1. Relationship between a Chronic Aerobic Exercise Intervention and the Variation of BDNF
Blood Concentration Levels in Human Models
The majority (n = 18) of the studies adopted a protocol of fewer than 12 weeks. An
increase in BDNF concentration levels was noted after the intervention in ten studies,
whilst 4 studies did not detect any variation as a result of an aerobic exercise program.
Some studies (n = 4) reported contradictory results. Concerning the 10 studies with an
intervention period ranging from 12 to 36 weeks, 6 of those studies reported no change
whatsoever, three an increase, and one contradictory results regarding BDNF concentration
levels. From the two studies of more than 36 weeks, one showed an increase and one a
decrease in the BDNF concentration levels after the exercise intervention.
From the twelve studies which proposed a PA intervention in healthy people, seven
presented no change in BDNF concentration levels, while a total of four studies cited an
increase, and one study reported a decrease in BDNF levels. In four studies concerning
people with cognitive impairments, one showed an increase in BDNF concentration levels
after a PA intervention, two studies presented no change whatsoever, and one displayed
contradictory results. Interestingly, the three studies on overweight and obese people
reported an increase in BDNF concentration levels after a PA intervention. The results
of PA interventions in schizophrenia or related disorders also seem to be positive, with
an increase of BDNF concentrations (n = 1). In depressed patients, two studies reported
an increase, whilst one study reported no change in BDNF levels after a PA intervention.
Studies concerning people with metabolic syndrome (n = 2) or type 2 diabetes (n = 1)
recorded no effects or decreases in BDNF concentrations after the intervention.
Training protocols on either a treadmill or free-running increased BDNF concentration
levels in six studies. The same number of studies reported no change after the intervention.
A decreased level in BDNF concentrations was reported in one study and contradictory
results were observed in three studies.
Alternately, on the cycle ergometer, an increase was observed in nine studies, while
no effect of training was seen in seven studies which adopted this type of PA intervention.
The results in two studies were conflicting. The only study with rowing ergometer training
presented no change in BDNF levels. Results are summarized in Table 1.
3.2. Relationship between a Chronic Aerobic Exercise Intervention and the Variation of BDNF
Blood Concentration Levels in Animal Models
Concerning the relationship between chronic aerobic exercise interventions and the
variation of BDNF blood concentration levels in animal models, 20 studies in total, which
met with the exclusion criteria, were extracted (Table 2). The duration between reports was
heterogeneous, with the time intervals ranging from 4- to 64-week protocols; the type of
exercise varied between swimming and treadmill running; the intensity was considered
similar between the articles exhibited in Table 2 (moderate-to-vigorous aerobic intensity).
The enzyme-linked immunosorbent assay (ELISA) was the most used analysis technique
(n = 14); other BDNF measures used were the Western Blot (n = 5) and the fluorescence-
based real-time PCR quantification method (n = 1). The studies (n= 20) displayed in Table 2,
regarding animal models, suggest that there seems to be a more consolidated agreement
amongst authors concerning the positive relationship between regular exercise training
and a consequent increase in BDNF production. Of the 20 articles included in Table 2,
18 denote an upregulation in BDNF concentration levels following an exercise protocol,
whereas 2 suggest no change whatsoever.
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Table 2. Summary of studies that have reviewed the relationship between a chronic aerobic exercise intervention and the variation of BDNF blood concentration levels in animal models.
Author(s) Population Studied (ExerciseGroup n vs. Control Group n) n
BDNF Measure









Ahn, et al. (2016) [55]
Aged Mongolian Gerbil Males
(Sham-Operated Group n = 14
Ischemia-Operated 1-week
Exercise Group n = 14 vs.
Ischemia-Operated 4-week
Exercise Group n = 14 vs. 4-week
Sedentary Ischemia-Operated
Control Group n = 14)
56 western blot post-intervention 1 and 4 weeks treadmill running(5 days/week) n.d.
In the Ischemia Operated 4-week
Sedentary Group, BDNF protein
levels were increased compared
with those in the Sham-Operated
Group; BDNF protein levels in the
Ischemia-Operated 4-week Exercise
Group were significantly increased
compared with the Ischemia
Operated 4-week Sedentary Group,
and Ischemia-Operated 1-week
Exercise Group. 4 weeks of exercise
(long-term exercise) enhanced the
BDNF expression.
Liu, et al. (2008) [56]
Male BALB/c Mice (Exercise
Group n = n.d. vs. Control Group
n = n.d.)
n.d. ELISA post-intervention 4 weeks treadmillexercise (5 days/week) n.d.
The exercise effect of training on
hippocampal BDNF level was
acute rather than chronic; training
transiently increased the
hippocampal BDNF level at 1, 2,
and 4 h post-exercise when
compared to the control.
Liu, et al. (2009) [57]
Male BALB/c Mice (Forced
Treadmill Exercise Group n = n.d.
vs. Control Group n = n.d.)
n.d. ELISA post-intervention 4 weeks treadmillexercise (5 days/week) n.d.
Training elevated BDNF levels.
Forced treadmill running
transiently elevated hippocampal
BDNF levels and significantly
increased BDNF levels in the
amygdala compared to the control.
Maejima, et al. (2018)
[18]
Senescence-Accelerated Mice
(Control Group n = 6 vs. Resistant
Exercise Group n = 6 vs. Prone
Sedentary Control Group n = 8 vs.
Prone Exercise Group n= 7)
27 ELISA post-intervention 4 weeks treadmill running(5 days/week) n.d.
The study revealed that aerobic
exercise for 4 weeks incresed
transcriptional and protein
expression levels of BDNF in mice.
Long-term exercise enhances the
expression of BDNF in the
hippocampus.
Skup, et al. (2002) [58]
Adult Male Wistar Rats (Exercise
Group n = 6 vs. Sedentary
Sedentary Control Group n = 6)
12 western blot post-intervention 4 weeks treadmillexercise (5 days/week) n.d.
Training enhanced expression of
BDNF in the spinal gray matter
fibers and, to a lesser extent,
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Table 2. Cont.
Author(s) Population Studied (ExerciseGroup n vs. Control Group n) n
BDNF Measure








Fahimi, et al. (2017) [59]
Adult Male C57BL/6 Mice
(Exercise Group n = 6 vs.
Non-Exercise Control Group n = 6)
12 ELISA post-intervention 5 weeks treadmill running(5–7 days/week) n.d.
BDNF significantly increased in
mRNA levels following long-term
exercise. A significant increase in
BDNF levels in the exercise group
was observed compared with the
non-exercise control group.
Seifart, et al. (2010) [47] Mice (Exercise Training Groupn = 8/Control Group n = 8) 16
fluorescence-based
real-time PCR post-intervention 5 weeks
treadmill running
(5 days/week) n.d.
The BDNF mRNA levels in the
hippocampus were higher in the
trained mice than in the untrained
mice from the control group. In the
cerebral cortex, the BDNF mRNA
levels were not significantly
elevated by training but were
comparable to those in the
hippocampus of the untrained
mice.
da Silva, et al. (2012)
[60]
Male Wistar Rats (Exercise Group
n = 27 vs. Control Group n = 27) 54 ELISA post-intervention ±5–6 weeks
treadmill (39 sessions
in total) n.d.
A significant increase in
hippocampal BDNF expression
was noted in the exercise group
(aerobic exercise program) when
compared with the control group.
Alomari, et al. (2013)
[61]
Male Wistar Rats (Forced Exercise
Group n = 14–15 vs. Control Group
n = 14–15)
28–
30 ELISA post-intervention 6 weeks
swimming
(5 days/week) n.d.
BDNF levels in the hippocampus
were greater in the forced exercise
training group when compared to
the control group. BDNF was
significantly higher in the forced
exercise than in the control group.
Jin, et al. (2017) [62]
Adult Male Sprague-Dawley Rats
(Young-Age Exercise Group n = 10
vs. Young-Age Control Group
n = 10 vs. Adult-Age Exercise
Group n = 10 vs. Adult-Age
Control Group n = 10)
40 western blot post-intervention 6 weeks treadmill running(7 days/week) n.d.
Treadmill exercise increased BDNF
expression in both young and
adult-aged rats compared with the
young and adult-aged control
groups.
So, et al. (2017) [63]
C57BL/6 Female Mice (Moderate
Exercise Group vs. Fatiguing
Exercise Group vs. Sedentary
Control Group)
n.d. ELISA post-intervention 6 weeks treadmill running(7 days/week) n.d.
The moderate exercise group had
significantly higher hippocampal
BDNF expression levels when
compared with the fatiguing
exercise group and with the
sedentary control group. No
significant difference was found
between the fatiguing and control
groups.
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Author(s) Population Studied (ExerciseGroup n vs. Control Group n) n
BDNF Measure








Uysal, et al. (2015) [64]
Wistar Albino Rats (Involuntary
Exercise Group n = 14 vs. Control
Group n = 14)
28 ELISA post-intervention 6 weeks treadmill running(5 days/week) n.d.
Prefrontal Cortex BDNF levels
were greater in the males of the
forced exercise group than in the
control group. The BDNF levels
were greater in females of the
forced exercise group than in
controls. Hippocampal BDNF
levels were increased in the forced
involuntary exercise group
compared with the sedentary
control group.
Cassilhas, et al. (2012)
[65]
Adult Male Wistar Rats (Aerobic
Exercise Group n = 11 vs. Sham
Group n = 11 vs. Control Group
n = 11)
33 ELISA post-intervention 8 weeks treadmill running(5 days/week) n.d.
A significantly higher level of
hippocampal BDNF was observed
in the Aerobic Exercise Group
compared with the Control Group.
Aerobic Exercise modulates BDNF.
Costa, et al. (2012) [66]
Young Adult and Middle-Aged
Male Wistar Rats (Young Adult
Treadmill Running 1 days/week vs.
Young Adult Treadmill Running
3 days/week vs. Young-Adult
Treadmill Running 7 days/week)
vs. Middle-Aged Treadmill
Running 1 days/week vs.
Middle-Aged Treadmill Running
3 days/week vs. Middle-Aged
Treadmill Running 7 days/week vs.
Young Adult Control Group vs.
Middle-Aged Control Group)
n.d. western blot post-intervention 8 weeks treadmill running(1/3/5 days/week) 60–75% VO2max
While a 1 day/week exercise
program caused an increase in both
proBDNF and BDNF in young rats,
the other frequencies of exercise
increased only BDNF levels when
compared with the control group.
The middle-aged exercise groups
presented an increase in BDNF
levels when compared with the
control group.




Exercise-Group n = 10 vs. 8-Week-
LongTerm-Exercise-Diabetic Group
n = 10 vs. Sedentary Diabetic
Group n = 10 vs. Control Group
n = 10)
40 ELISA post-intervention 2 and 8 weeks treadmill running(7 days/week) n.d.
No significant change on BDNF
levels was observed following a
short and long-term aerobic
exercise program compared with
control group. There was also no
significant difference between
groups with 2 and 8 weeks of
treadmill running in BDNF levels.
An exercise protocol did not
change significantly BDNF levels
in either group.
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Author(s) Population Studied (ExerciseGroup n vs. Control Group n) n
BDNF Measure









et al. (2015) [68]
Male Wistar Rats
(Moderate-Intensity Exercise
Group n = 6 vs. High-Intensity
Exercise Group n = 4 vs.
Moderate-Intensity Exercise Group
+ TrkB Inhibitor Injections n = 4 vs.
High-Intensity Exercise Group +
TrkB Inhibitor Injections n = 5 vs.
Sedentary Control Group n = 6)
25 ELISA post-intervention 8 weeks treadmill running(3 days/week)
moderate- or
high-intensity (60 or
80% of VO2 max)
Chronic treadmill exercise
significantly increased plasma
BDNF. After training, plasma
BDNF concentrations were
significantly higher in the trained
groups than those in the sedentary




Radak, et al. (2006) [69] Wistar Rats (Exercise Trained n = 7vs. Control n = 7) 14 ELISA
post-intervention at




increases the production of BDNF.
Exercise training significantly
increased the protein content of
BDNF, compared to control animal




Male Wistar Rats (2-week Exercise
Group n = 10 vs. 8-week Exercise
Group n = 10 vs. Control Group
n = 10)
30 ELISA post-intervention 2 and 8 weeks treadmill running(7 days/week) n.d.
Exercise did not change BDNF
content in the hippocampus of
trained animals. Neither long-term
(8 weeks) nor short-term (2 weeks)
exercise made any significant
change to BDNF levels in the
hippocampus.
Vilela, et al. (2017) [71]
Aging Wistar Rats (Aerobic
Training Group vs. Untrained
Control Group)
18 western blot post-intervention 8 weeks treadmill running(3–4 days/week) n.d.
BDNF levels were increased after
training for the aerobic exercise
group compared to the rats in the
untrained control group. The
results show BDNF levels
increased after aerobic training
>12 weeks
Pietrelli, et al. (2018)
[72]
Weaning Male Wistar Rats
(Aerobically Exercised (AE) Group
n = 30 vs. Sedentary Control Group
n = 30)





AE increased the BDNF
concentration in most of the brain
regions studied, nonetheless this
response was modulated by age
(significant differences due to
exercise in the striatum were only
seen among the old rats).
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3.3. Relationship between a Chronic Aerobic Exercise Intervention and the Variation of NT-4/5
Blood Concentration Levels in Animal Models
Differently from the studies regarding BDNF and long-term aerobic exercise protocols,
which consisted of study populations varying from human to animal models, the NT-4/5
studies concerning the relationship between aerobic exercise and the potential NT-4/5
variation in circulation levels, both centrally and peripherally, are only on animal models.
As to the relationship between chronic aerobic exercise interventions and the variation of
NT-4/5 blood concentration levels in animal models, two studies met our exclusion criteria
(Table 3). The minimum duration of the protocol intervention was, as previously stated,
of 4 weeks. The exercise modalities between reports were homologous, with treadmill
running being the preferred exercise modality amongst both authors’ studies. Again,
the intensity of the exercise between reports was analogous, having been considered as
moderate. The conclusions differ between reports; if on the one hand, one report suggests
that a long-term aerobic exercise protocol promotes a NT-4/5 expression upregulation, the
other appears to indicate that NT-4/5 showed no response whatsoever to exercise (Table 3).
Table 3. Summary of studies that have reviewed the relationship between a chronic aerobic exercise intervention and the
variation of NT-4/5 blood concentration levels in animal models.
Author(s)
Population Studied



























Control Group n = 6
vs. Resistant Exercise
Group n = 6 vs. Prone
Sedentary Control
Group n = 8 vs. Prone












only in SAMP, NT-4
protein did not










n = 6 vs. Sedentary
Control Group n = 6)










NTs, a family of closely related homodimeric polypeptide growth factors, were origi-
nally identified for their role in the survival, development, and function of neurons in both
central and peripheral nervous systems [73]. The discovery of nerve growth factor (NGF)
by Rita Levi di Montalcini and Viktor Hamburger, in the 1950s, represents a breakthrough
in the processes that led to modern-day cell biology [74]. After the discovery of NGF and
the understanding of the roles it plays in the central and peripheral nervous systems, other
neuron promoting neurotrophic factors belonging to the mammalian family were identified,
including BDNF, NT-3, and NT-4/5 [75]. These members appear to share a great amount of
structural and chemical similarities, including more than 50% of sequence homologies in
the primary structure, relatively similar molecular weights, and three disulfide bonds that
form a cysteine knot [8]. All NTs are synthesized as larger precursors known as proNTs,
and undergo proteolytic cleavage to become mature, biologically active, NTs [76]. These
neurotrophic factors exert their biological effects through the binding action from two
highly distinct receptors; the tyrosine kinase receptor (Trk), and a member of the tumor
necrosis factor superfamily known as the P75 neurotrophin receptor (p75NTR) [6,75]. Both
pro-NTs—the immature neurotrophic factor form—and mature neurotrophins—bind to
p75NTR; however, the mature proteins have more affinity with the three members of the
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tropomyosin-related kinase family of receptor tyrosine kinases [77] when compared to
p75NTR. Hence, mature NGF binds to TrkA, BDNF and NT-4/5 bind to TrkB, and NT-3
binds to TrkC [10]. However, there seems to occur a certain overlap, due to some redun-
dancy in the structures of the formerly cited neurotrophic factor cell surface receptors,
therefore, NT-3 can also bind to TrkA and TrkB, although with less affinity when com-
pared with the third Trk receptor counterpart, TrkC [10]. According to Phillips (2017) [78],
proneurotrophin binding to p75NTR, via activation of a receptor complex composed of
p75NTR and sortilin [79], are known to reduce spine complexity and density [80], induce
long-term depression [81], promote neuronal cell death [79], and facilitate the resculpting
of neuronal circuits [82]. In opposition to the immature neurotrophic binding interaction,
mature NTs, which bind to the Trk receptors, induce, according to Phillips (2017) [78], cell
survival and differentiation, dendritic spine complexity, long-term potentiation [83,84],
synaptic plasticity, and the resculpting of networks [85]. As aforesaid, only mature NTs
bind to the Trk receptors, resulting in the activation of three main pathways: Ras, primarily
responsible for the control of normal survival and differentiation by activating mitogen-
activated protein kinase; phosphatidylinositol 3-kinase, which manages several neuronal
functions such as survival and neurite outgrowth through activation of the protein kinase
B, commonly known as AKT; and phospholipase C-γ1, which accounts for the control
of activity-dependent synaptic plasticity [8]. Similarly to the Trk receptors, p75NTR also
activates three major signaling pathways [86]. The first signaling pathway, NF-kappa B,
leads to the transcription of multiple genes; the second, through the activation of Jun kinase
via p75NTR, leads to neuronal apoptosis; and the last major signaling pathway, Rho activity,
controls the growth cone motility [86,87]. Regarding neurotrophic factor secretion, these
proteins are known to be produced, released and expressed from both neuronal and non-
neuronal cell populations across multiple tissue systems [8,13]. Consequently, although
these neurotrophic factors have been acknowledged as molecules responsible for neuronal
cell maintenance, it has been well established that they also possess a broad repertoire
of functions outside the nervous system [13,15]. Therefore, besides the aforementioned
role they exert in neurogenesis regulation, neuronal differentiation and survival, neuronal
plasticity, and neuronal conduction [88], they also seem to contribute to the promotion of
angiogenesis and survival of adult endothelial cells, vascular smooth muscle cells, and
cardiomyocytes; participate in the processes of inflammation and immunity interactions;
influence lipid metabolism control; and regulate type 2 diabetes mellitus [89].
4.1. BDNF
In 1982, BDNF, the second member of the neurotrophic family of neurotrophic fac-
tors, was discovered through the purification of a homogenized pig brain, where it was
recognized for its role in the growth and survival of sensory neurons [90]. Currently, BDNF
has been identified as a neurotrophic factor that supports the proliferation, survival and
differentiation of neurons in the peripheral and central nervous systems [91].
Although BDNF has been extensively characterized for the essential role it plays in
neuronal survival and development, known to serve as a neurotransmitter modulator,
and participate in neuronal plasticity [89,92], it also seems to promote actions on cardiac
and endothelial cells [93], act as a mediator between airway inflammatory events and
neuronal changes (inflammation and immunity) [89], affect energy metabolism (lipid
metabolism) [94,95], is also implicated in the cytoprotective action in type 2 diabetes
mellitus [96], and, through the ability of this neurotrophic factor to enhance neurogenesis
and consequently improve synaptic plasticity, as formerly discussed, evidence suggests
that it may be highly linked with multiple neurological conditions such as Alzheimer’s
disease, dementia, Huntington’s disease, bipolar disease, and autism [41,49,50].
As previously mentioned, the cellular processing of neurotrophic factors, especially of
BDNF, has been significantly reviewed throughout these past years within the literature [97].
Synthesis and maturation of BDNF consists of a multistage process, involving the sequen-
tial formation of numerous precursor isoforms [98]. BDNF is initially synthesized as a
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precursor, identified as a folded pre-pro-BDNF form in the endoplasmatic reticulum [98,99].
Subsequently, the pre-region sequence is removed upon translocation through the Golgi
membrane, yielding the 32 kDa isoform, consisting of 129 amino acid proteins of BDNF, also
referred to as pro-BDNF [98,99]. Consequently, following the cleavage of the signal peptide,
the pro-BDNF isoform is converted to a mature BDNF isoform (m-BDNF) by intracellular
(e.g., PC7, furin, and proconvertases), or by extracellular proteases (e.g., metalloproteinases
and plasmin), resulting in a 13 kDa polypeptide [30,54,55]. Accumulating evidence has
suggested that contrary to what was previously thought, both pro-BDNF and its mature
isoform, m-BDNF, are biologically active [100]. Furthermore, the mature form of BDNF
is identical between all mammals [101]. Regarding the interactions with different types
of receptors according to BDNF’s multiple isoforms, pro-BDNF interacts, preferentially,
with the p75NTR through its mature domain, and with the sortilin receptor [98], whereas
m-BDNF binds with the TrkB receptor [102]. This neurotrophic factor is found in elevated
concentrations in the CNS, predominantly in the brain regions of the hippocampus, cere-
bral cortex, hypothalamus, and cerebellum [103]. Central BDNF can cross the BBB and,
therefore, be found in the bloodstream. However, circulating BDNF can be derived from
multiple sources other than the CNS [104,105]. Accordingly, it has been well established
that a great number of tissues produce and release this neurotrophic substance, including
the lungs, bladder, intestinal tissue, vascular endothelial cells, skeletal and cardiac muscle,
peripheral neurons, peripheral blood mononuclear cells, and platelets [106–114]. Therefore,
it is seemingly difficult to ascertain the peripheric and brain contribution to the seric BDNF
levels [104].
The source of BDNF in the peripheral circulation raises several questions and is far
from being clear. In 2018, Naeglin et al. [115] searched for the range of BDNF levels that
could be considered normal in human blood. They found that BDNF can be measured in
human plasma, however, comparisons between populations were not reliable, consequently
needing future cohort studies. They also found a correlation between platelet and serum
BDNF. Nevertheless, the source of plasma/serum and platelet BDNF was not clarified.
On the other hand, a work by Chacón-Fernandéz and colleagues (2016) [116] referred
that the possible source of platelet BDNF are megakaryocytes, the progenitors of platelets.
Moreover, the same authors suggested that the induced-BDNF release by physical exercise
may reflect the changes that happen in megakaryocytes and platelets, including the ability
of the latter to retain and release BDNF. In spite of these articles, it is known, as referred to
previously, that other organs and tissues, such as the skeletal muscle, are able to produce
considerable amounts of BDNF during contraction (aerobic physical exercise); however,
the skeletal muscles contribution in the variation levels in plasma and brain BDNF remains
unclear.
4.2. NT-4/5
Although the trophic effects on central and peripheral neurons have been well-
established both in vivo and in vitro, NT-4, also referred to as NT-4/5, continues to be
the least studied member of the mammalian NT family [117]. According to László, et al.
(2019) [118], NT-4/5 is responsible for promoting survival and differentiation of hip-
pocampal, noradrenergic and dopaminergic neurons, as well as being involved in the
development of chemo-afferent sensory neurons known to innervate the carotid body;
furthermore, this neurotrophic factor has a strong survival and proliferative action on
NIH 3T3 cells expressing TrkB, however, it seems to have relatively limited activity on
3T3 cells expressing TrkA [119]. Except for being the most recently isolated neurotrophic
factor of the mammalian family, as well as being the least well understood, numerous
features seem to characterize this protein in a unique manner, when compared with its
mammalian neurotrophic family counterparts [120]. Thus, in contrast to the other NTs, its
expression is ubiquitous and appears to be less influenced by environmental signals [120];
in addition, it is also expressed at substantially inferior levels when compared with any
other neurotrophic factor [121].
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NT-4/5 was initially identified in xenopus and viper, having later been discovered
in both rats and humans [119]. The mature NT-4/5 sequences between human and rat
models are 95% identical at an amino-acid level [122]. Consequently, the immature form of
both human and rat NT-4/5 isoforms consists, respectively, of a 210 and a 209 amino-acid
sequence; following the removal of the prepropeptide, both human and rat NT-4/5, in its
mature form, consists of a 130 amino-acid chain [119], with a molar mass equivalent to
14 kDa [123]. Depending on its isoform—mature or immature—NT-4/5 exerts its biological
activities by binding to either TrkB or p75NTR [124,125].
In contrast to BDNF, NGF and NT-3, information concerning the sites of synthesis of
NT-4/5 are quite limited, with low concentrations being detected in the whole rat embryo,
the whole brain of the adult rat and in some rat and human peripheral tissues [122,126].
Concerning NT-4/5 detection within tissues, results revealed by Timmusk and colleagues
(1993) [121] show a developmentally regulated expression of NT-4/5 mRNA in most tissues,
with an apparent functional implication for NT-4/5 in the nervous system (e.g., ten brain
regions including x and y), as well as in peripheral and non-neuronal tissues (e.g., heart,
liver, muscle, skin, lung, kidney, thymus, spleen, submandibular gland, pituitary, thyroid,
testis, ovary); however, following conclusions presented by previous authors [122,126],
results from Timmusk and colleagues (1993) [121] reveal low levels of NT-4/5 mRNA in
a wide range of embryonic and adult rat tissues. Tissue distribution of human NT-4/5
transcripts was identified in a limited number of peripheral tissues, with the highest levels
found in the prostate and lower levels in the thymus, placenta, skeletal muscle, and the
testis; NT-4/5-hybridizing transcripts were not found in the brain [122]. This neurotrophic
factor is also present in human serum [127] and is also capable of crossing the BBB [22].
This is suggestive that these NTs can travel both ways: from the CNS to the periphery and
from the periphery into the brain.
4.3. Physical Exercise & Neurotrophic Factors
A kaleidoscope of significant benefits of PA, particularly aerobic exercise [9,128], on
human health, have long been correlated and predominantly include the decreased risk
of cardiovascular disease, diabetes, cancer, osteoporosis, and CNS diseases [9,129]. Only
recently, however, has it been admitted that PA may also stimulate a panoply of molecular
and cellular processes [130], known to modulate a cascade of chemical messengers referred
to as neurotransmitters and NTs, which act in an activity-dependent manner, resulting
in the potentiation of the neural function and in the induction of several events which
support the structural and functional plasticity of the brain [5,60,86]; nonetheless, the exact
mechanisms through which PA induces an upregulation of neurotrophic factor expression
have still not been fully elucidated.
The use of animals for scientific purposes is a relatively antique practice used in bio-
logical research and medicine, however, associated with this methodical scientific approach
is an array of recurrent ethical concerns [131,132]. There are extraordinary anatomical and
physiological similarities between human and animal mammalian models [131] and, as a
consequence, an extensive number of reports have been carried out to study and compre-
hend the relationship between PA and NTs in cellular and animal models [9]; however, it
must be taken into consideration that not all of the results can be forthrightly translated to
humans [131] and, therefore, must be interpreted with caution.
4.4. BDNF & Aerobic Exercise
BDNF is one of the most extensively reviewed neurotrophic factors belonging to the
mammalian family. Therefore, it is not surprising that there is a great number of reports
focusing and investigating the effects of PA, in particular aerobic exercise, on BDNF’s
concentration variation levels in both human and animal models. One major hallmark
related with the neurotrophic factor and physical exercise field of study was the discovery
of an active interface known as the BBB, which allows the crosstalk of certain substances
(e.g., polypeptides, such as NTs and cytokines) between the periphery and the CNS [133].
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4.5. NT-4/5 and Aerobic Exercise
Contrasting the great number of reports and consequential data available regarding
BDNF, a reasonably limited sum of studies have assessed the influence of long-term
aerobic exercise protocols on the variation levels of NT-4/5 in the cerebral and peripheral
circulation [9]. Peculiarly, NT-4/5 studies concerning the relationship between aerobic
exercise and the potential NT-4/5 variation in circulation levels, both cerebrally and
peripherally, only regard animal models. The conclusions differ markedly between reports;
if on one hand, the main outcome from one study [58] suggests that a long-term aerobic
exercise protocol promotes a NT-4/5 expression upregulation, the other [18] appears to
suggest that NT-4/5 showed no response whatsoever to exercise.
4.6. The Impact of Aerobic Exercise on Circulating Neurotrophin Levels (BDNF and NT-4/5) from
Cerebral and Peripheral Circulation: Which Organs Are the Main Contributors?
BDNF, which is present in the blood both at rest and during exercise training is, accord-
ing to Walsh & Tschakovsky (2018) [105], most likely derived from several tissue sources
(lungs, bladder, intestinal tissue, vascular endothelial cells, skeletal and cardiac muscle,
peripheral neurons, peripheral blood mononuclear cells, platelets, and the brain) known
to produce and release neurotrophic factors into circulation in response to exercise-like
stimuli [105–108,110,113]. As previously mentioned, contrary to BDNF and other members
of the neurotrophic factor family, information regarding NT-4/5 is limited. The conclu-
sions presented by Timmusk and colleagues (1993) [121] seem to be in accordance with
those also admitted by Ibañez (1996) [120] in the means that this neurotrophic substances
expression—NT-4/5—seems to be undoubtedly ubiquitous, found in a broad range of
tissues and organs, such as in the heart, liver, muscle, thymus, lung, kidney, testis, ovary,
salivary gland, cerebral cortex, brain stem and the hippocampus [121].
As it has been formerly stated, one major hallmark related to the neurotrophic factor
and PA field of study was the discovery of the BBB, which has been acknowledged in
enabling the crosstalk of NTs—e.g., BDNF and NT-4/5—through saturable transport
systems, between the periphery and the CNS [133]. Taken into account that both BDNF and
NT-4/5 have been found to be produced and expressed in a variety of tissues and organs,
and are correspondingly found in the periphery and CNS, suggesting the existence of a
neurotrophic crosstalk loop between systems through the BBB, it is of particular interest
to understand up to what extent these multiple cell-populations, known to produce and
express neurotrophic factors, contribute in the total amount of BDNF and NT-4/5 found in
the blood.
To date, the only study that seems to evaluate the contribution of the human brain to
plasma BDNF at rest and during prolonged whole-body exercise was one published by
Rasmussen and colleagues (2009) [134]. According to the previously mentioned author,
following a four-hour rowing ergometer protocol, completed by eight volunteers, and a
two-hour treadmill session, completed by 32 mice, the main outcomes were that in humans,
a BDNF release from the brain was detected at rest (p < 0.05), and increased two to threefold
during exercise (p < 0.05); concerning the mice study group, exercise provoked a three
to fivefold upsurge in BDNF mRNA expression in the hippocampus and cortex, peaking
2 h after the conclusion of the exercise protocol. The results obtained by Rasmussen and
colleagues (2009) determined that both at rest and during exercise, the brain contributed
for up to 70–80% of the circulating BDNF, consequently suggesting that the brain is, in fact,
the main, but not the only contributor, of circulating BDNF. On the other hand, in the case
of NT-4/5, to date, no study whatsoever has been conducted in the means to understand
up to what extent tissues from the CNS and from the periphery contribute to the NT-4/5
levels found in the blood.
This review has limitations. Firstly, the sample characteristics were not always speci-
fied by the authors, making it impossible for an accurate subgroup analysis. Furthermore,
the physical fitness levels of the participants that took part in the studies were not always
detected, making it difficult to evaluate the conclusions of the included studies. Addition-
Int. J. Mol. Sci. 2021, 22, 8814 22 of 28
ally, especially in the animals’ model studies, the inconsistencies in the duration, type and
intensity of the exercise interventions, as well as specific methodological considerations
such as blood processing conditions (plasma, serum or platelet), contributed to the subse-
quent variability of results. Further reports, with both increased sample sizes and longer
durations, are needed to evaluate the effect of a chronic aerobic exercise intervention on
blood BDNF and NT-4/5 concentrations in a more conclusive manner. Moreover, addi-
tional research regarding the relationship between peripheral and cerebral concentrations
of both BDNF and NT-4/5 is required to evaluate the effect of long-term (chronic) aerobic
exercise on the BDNF and NT-4/5 concentration levels in the blood.
5. Conclusions
This review provides, firstly, an updated overview on the evidence concerning the
role that long-term aerobic exercise programs may induce on BDNF and NT-4/5 blood
concentration levels and, secondly, attempted to understand up to what extent the literature
studied the contribution of cerebral and peripheral BDNF and NT-4/5 secreting cell-
populations, responsible for these NTs found in the blood.
Regarding the relationship between BDNF and long-term aerobic exercise protocols,
studies performed in human populations appear to demonstrate a certain level of ambiguity
on the effects that PA, more specifically aerobic exercise, provokes in the stimulation and
enhancement of BDNF blood concentration levels. On the other hand, in animal models,
the BDNF and long-term aerobic exercise protocol relationship appears to be relatively
unquestionable, in the means that regular exercise training does, indeed, in most cases,
lead to an increase in BDNF concentration levels found in the blood.
Concerning the relationship between NT-4/5 and long-term aerobic exercise protocols,
evidence is fairly inconsistent due to the lack of studies, consequently making it difficult to
reach a final conclusion.
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